Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06433804
Status:
COMPLETED
Last Update Posted:
2024-05-30
First Post:
2024-05-16
Brief Title:
Clinicopathological Parameters of HER2 Low Breast Cancers
Sponsor:
Vardhman Mahavir Medical College And Safdarjung Hospital
Organization:
Vardhman Mahavir Medical College And Safdarjung Hospital
Study Overview
Official Title:
Exploring the Clinicopathological Parameters of HER2 Low Breast Cancers
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a retrospective cohort study which included all histologically proven cases of breast cancer in the 2 years from January 2022- December 2023 at a tertiary care centre
This study was performed in line with STROCSS criteria The following clinicopathological data was retrieved from the histopathological records- age tumor size nodal involvement lymphovascular perineural invasion and Bloom Richardson grading
Routine histopathological processing was done followed by immunohistochemical analysis for ER PR HER2 Ki67 and AR All the cases were categorised into Luminal A B Her2 enriched and triple-negative breast cancer based on the surrogate molecular classification Further all the cases were categorised into HER2 negative no staining or incomplete weak membrane staining in 10 tumor cells HER2 3 complete membranous staining and HER2 low 1-2 staining without amplification on ISH based on consensus of two pathology consultants The present study aims to evaluate the clinicopathological parameters of the HER2 low breast cancers
This study was performed in line with STROCSS criteria The following clinicopathological data was retrieved from the histopathological records- age tumor size nodal involvement lymphovascular perineural invasion and Bloom Richardson grading
Routine histopathological processing was done followed by immunohistochemical analysis for ER PR HER2 Ki67 and AR All the cases were categorised into Luminal A B Her2 enriched and triple-negative breast cancer based on the surrogate molecular classification Further all the cases were categorised into HER2 negative no staining or incomplete weak membrane staining in 10 tumor cells HER2 3 complete membranous staining and HER2 low 1-2 staining without amplification on ISH based on consensus of two pathology consultants The present study aims to evaluate the clinicopathological parameters of the HER2 low breast cancers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None